The role of ubiquitin-binding domains in human pathophysiology

References

• Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425–79
   PubMed Web of Science ®Google Scholar
• Varshavsky A. Regulated protein degradation. Trends Biochem Sci 2005;30:283–6
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007;315:201–5
   PubMed Web of Science ®Google Scholar
• Hirsch C, Gauss R, Horn SC, et al. The ubiquitylation machinery of the endoplasmic reticulum. Nature 2009;458:453–60
   PubMed Web of Science ®Google Scholar
• Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011;12:439–52
   PubMed Web of Science ®Google Scholar
• Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. Mol Cell 2009;34:259–69
   PubMed Web of Science ®Google Scholar
• Elsasser S, Finley D. Delivery of ubiquitinated substrates to protein-unfolding machines. Nat Cell Biol 2005;7:742–9
   PubMed Web of Science ®Google Scholar
• Staub O, Rotin D. Role of ubiquitylation in cellular membrane transport. Physiol Rev 2006;86:669–707
   PubMed Web of Science ®Google Scholar
• Huang TT, D’Andrea AD. Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol 2006;7:323–34
   PubMed Web of Science ®Google Scholar
• Raiborg C, Bache KG, Gillooly DJ, et al. Hrs sorts ubiquitinated proteins into clathrin-coated microdomains of early endosomes. Nat Cell Biol 2002;4:394–8
   PubMed Web of Science ®Google Scholar
• Hurley JH, Lee S, Prag G. Ubiquitin-binding domains. Biochem J 2006;399:361–72
   PubMed Web of Science ®Google Scholar
• Hicke L, Schubert HL, Hill CP. Ubiquitin-binding domains. Nat Rev Mol Cell Biol 2005;6:610–21
   PubMed Web of Science ®Google Scholar
• Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains – from structures to functions. Nat Rev Mol Cell Biol 2009;10:659–71
   PubMed Web of Science ®Google Scholar
• Komander D, Rape M. The ubiquitin code. Annu Rev Biochem 2012;81:203–29
   PubMed Web of Science ®Google Scholar
• Ciechanover A, Ben-Saadon R. N-terminal ubiquitination: more protein substrates join in. Trends Cell Biol 2004;14:103–6
   PubMed Web of Science ®Google Scholar
• Ravid T, Hochstrasser M. Autoregulation of an E2 enzyme by ubiquitin-chain assembly on its catalytic residue. Nat Cell Biol 2007;9:422–7
   PubMed Web of Science ®Google Scholar
• Wang XL, Herr RA, Chua WJ, et al. Ubiquitination of serine, threonine, or lysine residues on the cytoplasmic tail can induce ERAD of MHC-I by viral E3 ligase mK3. J Cell Biol 2007;177:613–24
   PubMed Web of Science ®Google Scholar
• Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001;70:503–33
   PubMed Web of Science ®Google Scholar
• Chau V, Tobias JW, Bachmair A, et al. A multiubiquitin chain is confined to specific lysise in a targeted short-lived protein. Science 1989;243:1576–83
   PubMed Web of Science ®Google Scholar
• Cook WJ, Jeffrey LC, Carson M, et al. Structure of a diubiquitin conjugate and a model for interaction with ubiquitin conjugating enzyme (E2). J Biol Chem 1992;267:16467–71
   PubMed Web of Science ®Google Scholar
• Sun LJ, Chen ZJ. The novel functions of ubiquitination in signaling. Curr Opin Cell Biol 2004;16:119–26
   PubMed Web of Science ®Google Scholar
• Hicke L, Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 2003;19:141–72
   PubMed Web of Science ®Google Scholar
• Spence J, Gali RR, Dittmar G, et al. Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 2000;102:67–76
   PubMedGoogle Scholar
• Komander D. The emerging complexity of protein ubiquitination. Biochem Soc Trans 2009;37:937–53
   PubMed Web of Science ®Google Scholar
• Wu-Baer F, Lagrazon K, Yuan W, Baer R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J Biol Chem 2003;278:34743–6
   PubMed Web of Science ®Google Scholar
• Morris JR, Solomon E. BRCA1: BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum Mol Genet 2004;13:807–17
   PubMedGoogle Scholar
• Kirisako T, Kamei K, Murata S, et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 2006;25:4877–87
   PubMed Web of Science ®Google Scholar
• Iwai K, Tokunaga F. Linear polyubiquitination: a new regulator of NF-kappaB activation. EMBO Rep 2009;10:706–13
   PubMed Web of Science ®Google Scholar
• Tokunaga F, Sakata S, Saeki Y, et al. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol 2009;11:123–32
   PubMed Web of Science ®Google Scholar
• Rahighi S, Ikeda F, Kawasaki M, et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation. Cell 2009;136:1098–109
   PubMed Web of Science ®Google Scholar
• Nakasone Mark A, Livnat-Levanon N, Glickman Michael H, et al. Mixed-linkage ubiquitin chains send mixed messages. Structure (London, England: 1993) 2013;21:727–40
   Google Scholar
• Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals – ‘protein modifications: beyond the usual suspects’ review series. EMBO Rep 2008;9:536–42
   PubMed Web of Science ®Google Scholar
• Husnjak K, Dikic I. Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. Annu Rev Biochem 2012;81:291–322
   PubMed Web of Science ®Google Scholar
• Kulathu Y, Komander D. Atypical ubiquitylation – the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 2012;13:508–23
   PubMed Web of Science ®Google Scholar
• Massey LK, Mah AL, Ford DL, et al. Overexpression of ubiquilin decreases ubiquitination and degradation of presenilin proteins. J Alzheimers Dis 2004;6:79–92
   PubMedGoogle Scholar
• Raasi S, Pickart CM. Rad23 ubiquitin-associated domains (UBA) inhibit 26 S proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains. J Biol Chem 2003;278:8951–9
   PubMedGoogle Scholar
• Brignone C, Bradley KE, Kisselev AF, Grossman SR. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene 2004;23:4121–9
   PubMedGoogle Scholar
• Walters KJ, Lech PJ, Goh AM, et al. DNA-repair protein hHR23a alters its protein structure upon binding proteasomal subunit S5a. Proc Natl Acad Sci USA 2003;100:12694–9
   PubMed Web of Science ®Google Scholar
• Deveraux Q, Ustrell V, Pickart C, Rechsteiner M. A 26-S protease subunit that binds ubiquitin conjugates. J Biol Chem 1994;269:7059–61
   PubMed Web of Science ®Google Scholar
• Fisher RD, Wang B, Alam SL, et al. Structure and ubiquitin binding of the ubiquitin-interacting motif. J Biol Chem 2003;278:28976–84
   PubMedGoogle Scholar
• Lee S, Tsai YC, Mattera R, et al. Structural basis for ubiquitin recognition and autoubiquitination by Rabex-5. Nat Struct Mol Biol 2006;13:264–71
   PubMedGoogle Scholar
• Hirano S, Kawasaki M, Ura H, et al. Double-sided ubiquitin binding of Hrs-UIM in endosomal protein sorting. Nat Struct Mol Biol 2006;13:272–7
   PubMedGoogle Scholar
• Haririnia A, Verma R, Purohit N, et al. Mutations in the hydrophobic core of ubiquitin differentially affect its recognition by receptor proteins. J Mol Biol 2008;375:979–96
   Google Scholar
• Penengo L, Mapelli M, Murachelli AG, et al. Crystal structure of the ubiquitin binding domains of rabex-5 reveals two modes of interaction with ubiquitin. Cell 2006;124:1183–95
   PubMed Web of Science ®Google Scholar
• VanDemark AP, Hofmann RM, Tsui C, et al. Molecular insights into polyubiquitin chain assembly: crystal structure of the Mms2/Ubc13 heterodimer. Cell 2001;105:711–20
   PubMed Web of Science ®Google Scholar
• Wu T, Merbl Y, Huo Y, et al. UBE2S drives elongation of K11-linked ubiquitin chains by the anaphase-promoting complex. Proc Natl Acad Sci USA 2010;107:1355–60
   PubMed Web of Science ®Google Scholar
• Chen Z, Pickart CM. A 25-kilodalton ubiquitin carrier protein (E2) catalyzes multi-ubiquitin chain synthesis via lysine 48 of ubiquitin. J Biol Chem 1990;265:21835–42
   PubMedGoogle Scholar
• Wilson RC, Edmondson SP, Flatt JW, et al. The E2-25K ubiquitin-associated (UBA) domain aids in polyubiquitin chain synthesis and linkage specificity. Biochem Biophys Res Commun 2011;405:662–6
   Google Scholar
• Song S, Kim S-Y, Hong Y-M, et al. Essential role of E2-25K/Hip-2 in mediating amyloid-β neurotoxicity. Mol Cell 2003;12:553–63
   PubMedGoogle Scholar
• Barnham KJ, Cappai R, Beyreuther K, et al. Delineating common molecular mechanisms in Alzheimer’s and prion diseases. Trends Biochem Sci 2006;31:465–72
   PubMed Web of Science ®Google Scholar
• van Leeuwen FW, de Kleijn DP, van den Hurk HH, et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer’s and Down patients. Science 1998;279:242–7
   PubMed Web of Science ®Google Scholar
• De Vrij FM, Sluijs JA, Gregori L, et al. Mutant ubiquitin expressed in Alzheimer’s disease causes neuronal death. FASEB J 2001;15:2680–8
   PubMed Web of Science ®Google Scholar
• Lindsten K, de Vrij FMS, Verhoef LGGC, et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol 2002;157:417–27
   PubMedGoogle Scholar
• Ko S, Kang GB, Song SM, et al. Structural basis of E2-25K/UBB + 1 interaction leading to proteasome inhibition and neurotoxicity. J Biol Chem 2010;285:36070–80
   PubMed Web of Science ®Google Scholar
• de Pril R, Fischer DF, Roos RA, van Leeuwen FW. Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases. Mol Cell Neurosci 2007;34:10–19
   PubMedGoogle Scholar
• Reyes-Turcu FE, Horton JR, Mullally JE, et al. The ubiquitin binding domain ZnFUBP recognizes the C-terminal diglycine motif of unanchored ubiquitin. Cell 2006;124:1197–208
   PubMed Web of Science ®Google Scholar
• Sokratous K, Roach LV, Channing D, et al. Probing affinity and ubiquitin linkage selectivity of ubiquitin-binding domains using mass spectrometry. J Am Chem Soc 2012;134:6416–24
   Google Scholar
• Raasi S, Orlov I, Fleming KG, Pickart CM. Binding of polyubiquitin chains to ubiquitin-associated (UBA) domains of HHR23A. J Mol Biol 2004;341:1367–79
   PubMedGoogle Scholar
• Raasi S, Varadan R, Fushman D, Pickart CM. Diverse polyubiquitin interaction properties of ubiquitin-associated domains. Nat Struct Mol Biol 2005;12:708–14
   PubMed Web of Science ®Google Scholar
• Varadan R, Assfalg M, Raasi S, et al. Structural determinants for selective recognition of a lys48-linked polyubiquitin chain by a UBA domain. Mol Cell 2005;18:687–98
   Google Scholar
• Castaneda CA, Kashyap TR, Nakasone MA, et al. Unique structural, dynamical, and functional properties of k11-linked polyubiquitin chains. Structure 2013;21:1168–81
   Google Scholar
• Zhang D, Raasi S, Fushman D. Affinity makes the difference: nonselective interaction of the UBA domain of ubiquilin-1 with monomeric ubiquitin and polyubiquitin chains. J Mol Biol 2008;377:162–80
   PubMed Web of Science ®Google Scholar
• Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006;2006:re13
   PubMedGoogle Scholar
• Wu CJ, Conze DB, Li T, et al. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol 2006;8:398–406
   PubMed Web of Science ®Google Scholar
• Ea CK, Deng L, Xia ZP, et al. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006;22:245–57
   PubMed Web of Science ®Google Scholar
• Bloor S, Ryzhakov G, Wagner S, et al. Signal processing by its coil zipper domain activates IKK gamma. Proc Natl Acad Sci USA 2008;105:1279–84
   Google Scholar
• Wagner S, Carpentier I, Rogov V, et al. Ubiquitin binding mediates the NF-kappaB inhibitory potential of ABIN proteins. Oncogene 2008;27:3739–45
   PubMedGoogle Scholar
• Lo YC, Lin SC, Rospigliosi CC, et al. Structural basis for recognition of diubiquitins by NEMO. Mol Cell 2009;33:602–15
   Google Scholar
• Doffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet 2001;27:277–85
   PubMed Web of Science ®Google Scholar
• Filipe-Santos O, Bustamante J, Haverkamp MH, et al. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med 2006;203:1745–59
   PubMed Web of Science ®Google Scholar
• Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci USA 1996;93:6721–5
   PubMed Web of Science ®Google Scholar
• Wang YY, Li L, Han KJ, et al. A20 is a potent inhibitor of TLR3- and Sendai virus-induced activation of NF-kappaB and ISRE and IFN-beta promoter. FEBS Lett 2004;576:86–90
   Google Scholar
• Sarma V, Lin Z, Clark L, et al. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem 1995;270:12343–6
   PubMed Web of Science ®Google Scholar
• Fries KL, Miller WE, Raab-Traub N. The A20 protein interacts with the Epstein–Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex. Virology 1999;264:159–66
   PubMed Web of Science ®Google Scholar
• Graham RR, Cotsapas C, Davies L, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 2008;40:1059–61
   PubMed Web of Science ®Google Scholar
• Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008;40:1062–4
   PubMed Web of Science ®Google Scholar
• Hammer GE, Turer EE, Taylor KE, et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol 2011;12:1184–93
   PubMed Web of Science ®Google Scholar
• Vereecke L, Sze M, Mc Guire C, et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med 2010;207:1513–23
   PubMed Web of Science ®Google Scholar
• Matmati M, Jacques P, Maelfait J, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011;43:908–12
   PubMed Web of Science ®Google Scholar
• Kool M, van Loo G, Waelput W, et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011;35:82–96
   PubMed Web of Science ®Google Scholar
• Tavares RM, Turer EE, Liu CL, et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010;33:181–91
   PubMed Web of Science ®Google Scholar
• Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010;327:1135–9
   PubMed Web of Science ®Google Scholar
• Wertz IE, O’Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004;430:694–9
   PubMed Web of Science ®Google Scholar
• Skaug B, Chen J, Du F, et al. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol Cell 2011;44:559–71
   PubMed Web of Science ®Google Scholar
• Verhelst K, Carpentier I, Kreike M, et al. A20 inhibits LUBAC-mediated NF-κB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J 2012;31:3845–55
   PubMed Web of Science ®Google Scholar
• Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712–16
   PubMed Web of Science ®Google Scholar
• Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206:981–9
   PubMed Web of Science ®Google Scholar
• Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007;12:1543–68
   PubMed Web of Science ®Google Scholar
• Gyrd-Hansen M, Darding M, Miasari M, et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol 2008;10:1309–17
   PubMed Web of Science ®Google Scholar
• Layfield R, Ciani B, Ralston SH, et al. Structural and functional studies of mutations affecting the UBA domain of SQSTM1 (p62) which cause Paget's disease of bone. Biochem Soc Trans 2004;32:728–30
   PubMed Web of Science ®Google Scholar
• Cavey JR, Ralston SH, Sheppard PW, et al. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. Calcif Tissue Int 2006;78:271–7
   PubMed Web of Science ®Google Scholar
• Visconti MR, Langston AL, Alonso N, et al. Mutations of SQSTM1 are associated with severity and clinical outcome in paget disease of bone. J Bone Miner Res 2010;25:2368–73
   PubMed Web of Science ®Google Scholar
• Michou L, Collet C, Laplanche JL, et al. Genetics of Paget’s disease of bone. Joint Bone Spine 2006;73:243–8
   PubMed Web of Science ®Google Scholar
• Garner TP, Long J, Layfield R, Searle MS. Impact of p62/SQSTM1 UBA domain mutations linked to Paget’s disease of bone on ubiquitin recognition. Biochemistry 2011;50:4665–74
   PubMed Web of Science ®Google Scholar
• Goode A, Layfield R. Recent advances in understanding the molecular basis of Paget disease of bone. J Clin Pathol 2010;63:199–203
   PubMed Web of Science ®Google Scholar
• Rea SL, Walsh JP, Layfield R, et al. New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget's disease of bone. Endocr Rev 2013;34:501–24
   PubMed Web of Science ®Google Scholar
• Hoege C, Pfander B, Moldovan GL, et al. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 2002;419:135–41
   PubMed Web of Science ®Google Scholar
• Tomida J, Masuda Y, Hiroaki H, et al. DNA damage-induced ubiquitylation of RFC2 subunit of replication factor C complex. J Biol Chem 2008;283:9071–9
   PubMed Web of Science ®Google Scholar
• Bergink S, Salomons FA, Hoogstraten D, et al. DNA damage triggers nucleotide excision repair-dependent monoubiquitylation of histone H2A. Genes Dev 2006;20:1343–52
   PubMed Web of Science ®Google Scholar
• Smogorzewska A, Matsuoka S, Vinciguerra P, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007;129:289–301
   PubMed Web of Science ®Google Scholar
• Hofmann K. Ubiquitin-binding domains and their role in the DNA damage response. DNA Repair (Amst) 2009;8:544–56
   PubMed Web of Science ®Google Scholar
• Kim H, Chen J, Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007;316:1202–5
   PubMed Web of Science ®Google Scholar
• Kolas NK, Chapman JR, Nakada S, et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 2007;318:1637–40
   PubMed Web of Science ®Google Scholar
• Mailand N, Bekker-Jensen S, Faustrup H, et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007;131:887–900
   PubMed Web of Science ®Google Scholar
• Huen MS, Grant R, Manke I, et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 2007;131:901–14
   PubMed Web of Science ®Google Scholar
• Doil C, Mailand N, Bekker-Jensen S, et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 2009;136:435–46
   PubMed Web of Science ®Google Scholar
• Pinato S, Scandiuzzi C, Arnaudo N, et al. RNF168, a new RING finger, MIU-containing protein that modifies chromatin by ubiquitination of histones H2A and H2AX. BMC Mol Biol 2009;10:55
   PubMed Web of Science ®Google Scholar
• Pinato S, Gatti M, Scandiuzzi C, et al. UMI, a novel RNF168 ubiquitin binding domain involved in the DNA damage signaling pathway. Mol Cell Biol 2011;31:118–26
   PubMedGoogle Scholar
• Cao J, Yan Q. Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer. Front Oncol 2012;2:26
   PubMedGoogle Scholar
• Lehmann AR. DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie 2003;85:1101–11
   PubMed Web of Science ®Google Scholar
• Licht CL, Stevnsner T, Bohr VA. Cockayne syndrome group B cellular and biochemical functions. Am J Hum Genet 2003;73:1217–39
   PubMedGoogle Scholar
• Hanawalt PC, Spivak G. Transcription-coupled DNA repair: two decades of progress and surprises. Nat Rev Mol Cell Biol 2008;9:958–70
   PubMed Web of Science ®Google Scholar
• Anindya R, Mari P-O, Kristensen U, et al. A ubiquitin-binding domain in Cockayne syndrome B required for transcription-coupled nucleotide excision repair. Mol Cell 2010;38:637–48
   PubMed Web of Science ®Google Scholar
• Taniguchi T, D’Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006;107:4223–33
   PubMed Web of Science ®Google Scholar
• Moldovan G-L, D’Andrea AD. How the Fanconi anemia pathway guards the genome. Annu Rev Genet 2009;43:223–49
   PubMed Web of Science ®Google Scholar
• Auerbach AD, Wolman SR. Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature 1976;261:494–6
   PubMed Web of Science ®Google Scholar
• Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001;7:249–62
   PubMed Web of Science ®Google Scholar
• Sims AE, Spiteri E, Sims RJ, et al. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol 2007;14:564–7
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Garcia-Higuera I, Andreassen PR, et al. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002;100:2414–20
   PubMed Web of Science ®Google Scholar
• Wang X, Andreassen PR, D’Andrea AD. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004;24:5850–62
   PubMed Web of Science ®Google Scholar
• Cybulski KE, Howlett NG. FANCP/SLX4: a Swiss army knife of DNA interstrand crosslink repair. Cell Cycle 2011;10:1757–63
   PubMed Web of Science ®Google Scholar
• Kim Y, Lach FP, Desetty R, et al. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011;43:142–6
   PubMed Web of Science ®Google Scholar
• Kratz K, Schopf B, Kaden S, et al. Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. Cell 2010;142:77–88
   PubMed Web of Science ®Google Scholar
• MacKay C, Declais AC, Lundin C, et al. Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell 2010;142:65–76
   PubMed Web of Science ®Google Scholar
• Smogorzewska A, Desetty R, Saito TT, et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell 2010;39:36–47
   PubMed Web of Science ®Google Scholar
• Stoepker C, Hain K, Schuster B, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011;43:138–41
   PubMed Web of Science ®Google Scholar
• Rego MA, Kolling FW, Vuono EA, et al. Regulation of the Fanconi anemia pathway by a CUE ubiquitin-binding domain in the FANCD2 protein. Blood 2012;120:2109–17
   Google Scholar
• Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006;6:776–88
   PubMed Web of Science ®Google Scholar
• Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006;6:369–81
   PubMed Web of Science ®Google Scholar
• Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008;14:10–21
   PubMed Web of Science ®Google Scholar
• Satija YK, Bhardwaj A, Das S. A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer. Int J Cancer 2013;133:2759–68
   PubMed Web of Science ®Google Scholar
• Sgorbissa A, Potu H, Brancolini C. Isopeptidases in anticancer therapy: looking for inhibitors. Am J Transl Res 2010;2:235–47
   PubMedGoogle Scholar
• Nicholson B, Marblestone JG, Butt TR, Mattern MR. Deubiquitinating enzymes as novel anticancer targets. Future Oncol 2007;3:191–9
   PubMedGoogle Scholar
• Bienko M, Green CM, Crosetto N, et al. Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis. Science 2005;310:1821–4
   PubMed Web of Science ®Google Scholar
• Guo C, Tang TS, Bienko M, et al. Ubiquitin-binding motifs in REV1 protein are required for its role in the tolerance of DNA damage. Mol Cell Biol 2006;26:8892–900
   PubMed Web of Science ®Google Scholar
• Masutani C, Kusumoto R, Yamada A, et al. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature 1999;399:700–4
   PubMed Web of Science ®Google Scholar
• Johnson RE, Kondratick CM, Prakash S, Prakash L. hRAD30 mutations in the variant form of xeroderma pigmentosum. Science 1999;285:263–5
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349–60
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–17
   PubMed Web of Science ®Google Scholar
• Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006;14:451–6
   PubMed Web of Science ®Google Scholar
• Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009;458:438–44
   PubMed Web of Science ®Google Scholar
• Fulda S, Rajalingam K, Dikic I. Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med 2012;4:545–56
   Google Scholar
• Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes Bortezomib resistance. Cancer Cell 2012;22:345–58
   PubMed Web of Science ®Google Scholar
• Verma R, Peters NR, D’Onofrio M, et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 2004;306:117–20
   PubMed Web of Science ®Google Scholar
• Husnjak K, Elsasser S, Zhang NX, et al. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 2008;453:481–8
   PubMed Web of Science ®Google Scholar
• Hayden MS, Ghosh S. Shared principles in NF-B signaling. Cell 2008;132:344–62
   PubMed Web of Science ®Google Scholar
• Perkins ND. Integrating cell-signalling pathways with NF-kappa B and IKK function. Nat Rev Mol Cell Biol 2007;8:49–62
   PubMed Web of Science ®Google Scholar
• Scheidereit C. I kappa B kinase complexes: gateways to NF-kappa B activation and transcription. Oncogene 2006;25:6685–705
   PubMed Web of Science ®Google Scholar
• Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009;27:693–733
   PubMed Web of Science ®Google Scholar
• Chiaravalli J, Fontan E, Fsihi H, et al. Direct inhibition of NF-κB activation by peptide targeting the NOA ubiquitin binding domain of NEMO. Biochem Pharmacol 2011;82:1163–74
   Google Scholar
• Cornilescu G, Marquardt JL, Ottiger M, Bax A. Validation of protein structure from anisotropic carbonyl chemical shifts in a dilute liquid crystalline phase. J Am Chem Soc 1998;120:6836–7
   Google Scholar
• Alam SL, Sun J, Payne M, et al. Ubiquitin interactions of NZF zinc fingers. EMBO J 2004;23:1411–21
   PubMedGoogle Scholar